Work

[Docetaxel plus prednisone versus mitoxantrone plus prednisone as first-line chemotherapy for metastatic hormone-refractory prostate cancer: long-term effects and safety].

Year: 2012

Type: article

Study design: Clinical Trial

Source: PubMed

Authors: Yi-jun Shen, Xiao-jie Bian, Hu-yang Xie, Yao Zhu, Hai-liang Zhang, Bo Dai, Shi-lin Zhang, Xu-dong Yao, Ding-wei Ye

Institutions: Shanghai Medical College of Fudan University, Fudan University, Fudan University Shanghai Cancer Center

Language: Chinese

Topic: Prostate Cancer Treatment and Research

Subfield: Cancer Research

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W178039927

FWCI:

Cites:

Cited by: 4

Related to: 10